de.advfn.com/...s=ilns&p=0&t=1&dm=1&vol=1&
Top-News
ILNS mit riesigen news
Beiträge: 28
Zugriffe: 1.873 / Heute: 1
Zugriffe: 1.873 / Heute: 1
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR S&P U.S. Technology Select Sector UCITS ETF
Perf. 12M: +40,41%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +39,64%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +38,30%
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +37,75%
SPDR MSCI Europe Technology UCITS ETF
Perf. 12M: +30,26%
Intellect Neurosciences, Inc. Obtains New Patent for Alzheimer's Vaccine From the United States Patent and Trademark Office ("US
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office ("USPTO") in relation to the Company's RECALL-VAXTM technology platform. Patents for RECALL-VAXTM have been issued in Europe, Australia, New Zealand and South Africa, and corresponding patent applications are pending in Canada, China, Japan and Israel. RECALL-VAXTM is a method to immunize people to produce highly specific natural antibodies against the beta amyloid ("Aβ") protein before it causes irreversible damage by accumulating in the brains of Alzheimer's patients. The vaccine has the potential to delay onset or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor. The approach can be applied to additional therapeutic targets associated with Alzheimer's and other neurodegenerative conditions. Professor Benjamin Chain, Department of Immunology, UCL School of Life and Medical Sciences, London, UK, is the inventor of RECALL-VAXTM. Professor Chain, brother of Dr. Daniel Chain, Intellect's Chairman and Chief Executive Officer, is a member of the Company's scientific advisory board.
Dr. Daniel Chain commented: "This new patent from the USPTO is yet another important milestone for the Company and is indicative of the type of ground breaking research we do that is aimed at discovering and developing drugs that can fundamentally transform the way Alzheimer's disease is treated and ultimately prevent the onset of the disease. Intellect has two immunotherapy approaches: The more advanced of the two is the ANTISENILIN® platform, which uses recombinant monoclonal antibodies as highly specific drugs to prevent the accumulation of soluble Aβ in the brains of Alzheimer's patients. The ANTISENILIN® technology underlies products under development by major pharmaceutical companies, such as Ponezumab in Phase 2 and Bapineuzumab in Phase 3 clinical trials, respectively. RECALL-VAXTM pinpoints the same unique molecular signatures at the ends of Aβ to reproduce the same type of specificity that can be obtained using ANTISENILIN® monoclonal antibodies. However, instead of administering antibodies to patients, RECALL-VAXTM involves injecting a small piece of Aβ coupled to an innocuous bacterial protein with the goal of allowing the patient's immune system to generate antibodies that uniquely bind Aβ. A vaccine of this nature, which is analogous to a flu shot, could be viewed as the ultimate quest in Alzheimer's research. We look forward to developing drug candidates based on RECALL-VAXTM technology with the aim of ultimately testing the vaccine in human clinical trials."
About Alzheimer's Disease
Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits, known as amyloid beta, on the surface of nerve cells, which results from the accumulation of soluble neurotoxic amyloid beta in the brain. The effects of the disease are devastating to patients as well as their caregivers, with significant associated health care costs. It is estimated that there are more than five million Americans and about 30 million people worldwide suffering from Alzheimer's disease, with the number expected to increase dramatically as the global population ages. Currently-marketed drugs transiently affect some symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. In the United States, Medicare spending on Alzheimer's disease is estimated to total $160 billion this year.
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced today that it has received a new patent from the United States Patent and Trademark Office ("USPTO") in relation to the Company's RECALL-VAXTM technology platform. Patents for RECALL-VAXTM have been issued in Europe, Australia, New Zealand and South Africa, and corresponding patent applications are pending in Canada, China, Japan and Israel. RECALL-VAXTM is a method to immunize people to produce highly specific natural antibodies against the beta amyloid ("Aβ") protein before it causes irreversible damage by accumulating in the brains of Alzheimer's patients. The vaccine has the potential to delay onset or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor. The approach can be applied to additional therapeutic targets associated with Alzheimer's and other neurodegenerative conditions. Professor Benjamin Chain, Department of Immunology, UCL School of Life and Medical Sciences, London, UK, is the inventor of RECALL-VAXTM. Professor Chain, brother of Dr. Daniel Chain, Intellect's Chairman and Chief Executive Officer, is a member of the Company's scientific advisory board.
Dr. Daniel Chain commented: "This new patent from the USPTO is yet another important milestone for the Company and is indicative of the type of ground breaking research we do that is aimed at discovering and developing drugs that can fundamentally transform the way Alzheimer's disease is treated and ultimately prevent the onset of the disease. Intellect has two immunotherapy approaches: The more advanced of the two is the ANTISENILIN® platform, which uses recombinant monoclonal antibodies as highly specific drugs to prevent the accumulation of soluble Aβ in the brains of Alzheimer's patients. The ANTISENILIN® technology underlies products under development by major pharmaceutical companies, such as Ponezumab in Phase 2 and Bapineuzumab in Phase 3 clinical trials, respectively. RECALL-VAXTM pinpoints the same unique molecular signatures at the ends of Aβ to reproduce the same type of specificity that can be obtained using ANTISENILIN® monoclonal antibodies. However, instead of administering antibodies to patients, RECALL-VAXTM involves injecting a small piece of Aβ coupled to an innocuous bacterial protein with the goal of allowing the patient's immune system to generate antibodies that uniquely bind Aβ. A vaccine of this nature, which is analogous to a flu shot, could be viewed as the ultimate quest in Alzheimer's research. We look forward to developing drug candidates based on RECALL-VAXTM technology with the aim of ultimately testing the vaccine in human clinical trials."
About Alzheimer's Disease
Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits, known as amyloid beta, on the surface of nerve cells, which results from the accumulation of soluble neurotoxic amyloid beta in the brain. The effects of the disease are devastating to patients as well as their caregivers, with significant associated health care costs. It is estimated that there are more than five million Americans and about 30 million people worldwide suffering from Alzheimer's disease, with the number expected to increase dramatically as the global population ages. Currently-marketed drugs transiently affect some symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. In the United States, Medicare spending on Alzheimer's disease is estimated to total $160 billion this year.
About Intellect Neurosciences, Inc.
warum muss man einen neuen thread eröffnen!
hmm
lg
hmm
lg
wie im lotto alles ist möglich!
kaufe aktien die keiner mehr haben will
und am ende wird alles gut!
kaufe aktien die keiner mehr haben will
und am ende wird alles gut!
wo wir heute hin fliegen :-)
das war ganz dünn. wird heute am start sofort die 004 knacken
ein schöner gapper
200k auf der 0,0027$ , scheint ein leichter wiederstand zu sein
der Umsatz geht mal ordentlich hoch, vieleicht weis ja jemand warum? ich Hab noch nichts gefunden. Wenn ich was finde stell ich es rein.
super heute nach dem Split, ich glaub schon knapp 10% aller Aktien nur der Kurs muss noch kommen. Vieleicht schaffen sie das mit ihren Produkt den Alzheimer Markt zu revolutionieren für mich ein großer Zukunfts Markt. Immer mehr alte Menschen und Alzheimer Kranke ein riesen Markt in der Zukunft. Bei den jetzigen Kursen kann man nicht viel falsch machen. Die Zukunft wird es zeigen ob sie Erfolg haben in ca. 2-3 Jahren vieleicht schon Milliardenwert wer weiß hop oder top.
finance.yahoo.com/news/Intellect-Neurosciences-prnews-845135613.html
Intellect Neurosciences Announces Its New CONJUMAB-A Platform Technology for Novel Treatments of Alzheimer's Disease and Other Proteinopathies
New platform of antibody drug conjugates to deliver potent cytoprotective drugs to sites of amyloidosis in brain and other organs
Neueste Beiträge aus dem Intellect Neurosciences Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 1 | US Bio Rakete ! | Theologe | Theologe | 26.10.11 17:54 | ||
2 | 27 | ILNS mit riesigen news | green2011 | Theologe | 26.10.11 16:01 | |
| 14 | habe mir heute welche gegönnt! | ARTNER514 | KungFuMaus | 31.03.11 18:59 |
